Hajime Karasuyama

Hajime Karasuyama

Auto-generated profile, based on publicly available information

Hajime Karasuyama

Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 1996 in Nature
Verified
Journal Article
Closed access
PDF file
KKKeisuke Kuida
Keisuke Kuida
TZTimothy S. Zheng
Timothy S. Zheng
SNSongqing Na
Songqing Na
CKChia-Yi Kuan
Chia-Yi Kuan
DYDi Yang
Di Yang
RFRichard A. Flavell
Richard A. Flavell

1 August 1998 in Cell
Verified
Journal Article
Open access
KKKeisuke Kuida
Keisuke Kuida
THTarik F Haydar
Tarik F Haydar
CKChia-Yi Kuan
Chia-Yi Kuan
YGYong Gu
Yong Gu
CTChoji Taya
Choji Taya
RFRichard A Flavell
Richard A Flavell
Caspases are essential components of the mammalian cell death machinery. Here we test the hypothesis that Caspase 9 (Casp9) is a critical upstream activator of caspases through gene targeting in mice. The majority of Casp9 knockout mice die perinatally with a markedly enlarged and malformed cerebrum caused by reduced apoptosis during brain development. Casp9 deletion prevents activation of Casp3 in embryonic brains in vivo, and Casp9-deficient thymocytes show resistance to a subset of apoptotic stimuli, including absence of Casp3-like cleavage and delayed DNA fragmentation. Moreover, the cytochrome c-mediated cleavage of Casp3 is absent in the cytosolic extracts of Casp9-deficient cells but is restored after addition of in vitro-translated Casp9. Together, these results indicate that Casp9 is a critical upstream activator of the caspase cascade in vivo.

5 August 2007 in Nature
Verified
Journal Article
Closed access
PDF file
YMYoshiyuki Minegishi
Yoshiyuki Minegishi
MSMasako Saito
Masako Saito
STShigeru Tsuchiya
Shigeru Tsuchiya
ITIkuya Tsuge
Ikuya Tsuge
HTHidetoshi Takada
Hidetoshi Takada
HKHajime Karasuyama
Hajime Karasuyama

1 February 1990 in Cell
Verified
Journal Article
Open access
EFEric R. Fearon
Eric R. Fearon
DPDrew M. Pardoll
Drew M. Pardoll
TIToshiuki Itaya
Toshiuki Itaya
PGPaul Golumbek
Paul Golumbek
HLHyam I. Levitsky
Hyam I. Levitsky
PFPhilip Frost
Philip Frost
A poorly immunogenic murine colon cancer was used to investigate mechanisms of antitumor immunity. Injection of tumor cells engineered by gene transfection to secrete IL-2 stimulated an MHC class I-restricted cytolytic T lymphocyte (CTL) response against the parental tumor. The tumor cells secreting IL-2 produced an antitumor response in vivo, even in the absence of CD4+ T cells. Animals immunized with the engineered cells were protected against subsequent challenge with the parental tumor cell line. Similar findings were demonstrated for other tumor types. Thus, provision of a helper lymphokine in a paracrine fashion induced a tumor-specific immune response involving activation of endogenous CTLs and other immune effector cells. These findings demonstrate that the failure of an effective antitumor immune response may be primarily due to a helper arm deficiency of the immune system rather than a paucity of tumor-specific cytotoxic effector cells. Furthermore, they outline a novel strategy for augmenting tumor immunity.

1 November 2006 in Immunity
Verified
Journal Article
Closed access
YMYoshiyuki Minegishi
Yoshiyuki Minegishi
MSMasako Saito
Masako Saito
TMTomohiro Morio
Tomohiro Morio
KWKen Watanabe
Ken Watanabe
KAKazunaga Agematsu
Kazunaga Agematsu
HKHajime Karasuyama
Hajime Karasuyama

1 November 1991 in Science
Verified
Journal Article
Closed access
PDF file
PGPaul T. Golumbek
Paul T. Golumbek
ALAudrey J. Lazenby
Audrey J. Lazenby
HLHyam I. Levitsky
Hyam I. Levitsky
LJLiz M. Jaffee
Liz M. Jaffee
HKHajime Karasuyama
Hajime Karasuyama
DPDrew M. Pardoll
Drew M. Pardoll
The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses of interleukin-4 (IL-4) locally, they were rejected in a predominantly T cell-independent manner. However, animals that rejected the IL-4-transfected tumors developed T cell-dependent systemic immunity to the parental tumor. This systemic immunity was tumor-specific and primarily mediated by CD8 + T cells. Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors. These results provide a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.